Amaria, R. N., Hauschild, A., Lowe, M., Taube, J. M., Daud, A., Truong, T., Weiss, S. A., Mangla, A., Miyani, T., Williams, D., Fang, F., Chen, S., Salvati, M., Lowy, I., Marullo, R., Fury, M. G., Lewis, K., Lara-Guerra, H. (2025). A randomized phase 2 peri-operative (neoadjuvant plus adjuvant) study of fianlimab (anti–LAG-3) plus cemiplimab (anti–PD-1) versus anti–PD-1 alone in patients with resectable stage III and IV melanoma.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2025.43.16_suppl.tps9596